Nob Hill Therapeutics is commercializing the first dry-powder nebulizer designed for high-dose lung delivery to treat severe respiratory diseases. This technology addresses the limitations of current inhalation therapies, enabling more effective medication administration for patients with conditions that are difficult to manage.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TVFounders
Product
Problem
Current inhalation therapies often struggle to deliver high doses of medication effectively to the lungs, limiting treatment options for patients with severe respiratory diseases. Existing nebulizers may not be suitable for all drug formulations or patient populations, resulting in suboptimal therapeutic outcomes.
Solution
Nob Hill Therapeutics is developing a dry-powder nebulizer designed to improve high-dose lung delivery for patients with severe respiratory diseases. Their technology aims to overcome the limitations of existing inhalation methods, enabling more effective medication administration. By re-envisioning inhalation medicines and how they are delivered, Nob Hill Therapeutics seeks to change the treatment paradigm for lung-related diseases that are difficult to manage with current approaches. The company is focused on developing new technologies and therapies to address unmet needs in respiratory patient care.
Target Audience
The primary target audience includes patients with severe respiratory diseases requiring high-dose inhaled medications, as well as healthcare providers specializing in respiratory care.
Features
- Dry-powder formulation for improved drug stability and delivery efficiency
- Nebulizer designed for high-dose lung delivery
- Technology suitable for a range of respiratory disease treatments